Effects of Andrographis Paniculate Extract in Patients with Asymptomatic and Mild Coronavirus 2019 Disease in a Community Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To collect the information on treatment outcomes of Andrographis paniculata extract on symptoms of patients with asymptomatic or mild coronavirus disease 2019 in a community hospital, and factors associated with pneumonia. Method: This research collected retrospective data from patients with COVID-19 receiving treatment at Paknam Chumphon Community Hospital during October to December 2021, who had no or mild symptoms, and treated with Andrographis paniculata extract (equivalent to 180 mg andrographolide /day) for 5 days. Study outcomes were symptomatic relief and pneumonia. Results: Among 150 participants, 58% were male. They had a mean age of 33.40±9.64 years and 98.7% had no non-communicable diseases. Their average BMI of was 22.93±4.79 kg/m2. 98.0% of them were not vaccinated against COVID-19. The most common manifestations were fever, cough and runny nose. After receiving Andrographis paniculata extract, the symptoms were relieved and cured at 3.9±3.3, 6.4±2.2 and 5.4±2.8 days, respectively. 35.3% of patients developed pneumonia. Pneumonia was identified on average at 4.52±2.05 days. Factor affecting the occurrence of pneumonia was alcohol drinking [odds ratio = 2.15, 95% CI = 1.02-4.54; P = 0.044). Conclusion: Asymptomatic COVID-19 patients or those with mild symptoms treated with Andrographis paniculata extract equivalent to 180 mg Andrographolide per day for 5 days showed improvement in clinical symptoms. 35.3% of treated patients developed pneumonia. Alcohol drinking was a factor affecting the occurrence of pneumonia in this group of patients
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
World Health Organization. Coronavirus disease (COVID-19). [online]. 2021 [cited Oct 20, 2021]. Available from: www.who.int/emergencies/diseases/ no vel-coronavirus-2019.
Siriboriruk J, Prueksaritanond S. COVID-19 is public health problem worldwide, including Thailand. Burapha Journal of Medicine. 2020; 7: 89-95.
Lung Disease and Respiratory Health. Coronavirus recovery [online]. 2022 [cited Jun 1, 20 22]. Available from: www.webmd.com/lung/covid-recovery-overview
Marini J.J., Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020; 323: 2329–30. doi: 10.1001/jama.2020.6825.
Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020; 71: 756-61.
Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karba laei M, Eslami M. A global treatment for coronaviruses including COVID-19. J Cell Physiol. 2020; 235: 9133-42.
Rismanbaf A. Potential treatments for COVID-19: A narrative literature review. Arch Acad Emerg Med. 2020; 8: e29.
Scavone C, Brusco S, Bertini M, Sportiello L, Rafa niello C, Zoccoli A, et al. Current pharmacological treatments for COVID‐19: What's next? Br J Pharma col. 2020; 177: 4813–24.
Roopkumdee J. Knowledge dissemination of civil defense volunteers in Nong Prue Municipality (Chonburi) in relation to using Kariyat herb for boosting. Journal of Pacific Institute of Management Science. 2020; 6: 422-27.
Chaiyasit K, Tokaew W, Boonsiri K. Medicinal plants and the communication on precautionary use of herbs during COVID-19 outbreak in Thailand. Bioact Compd Health Dis 2021; 4: 180-8.
Kongsangdao S. Antiviral drug in the research process for the treatment of Covid-19. Journal of the Department of Medical Services. 2020; 45: 5-8.
Rajagopal K, Varakumar P, Baliwada A, Byran G. Curcuma longa (turmeric) and Andrographis panicu lata against coronavirus (COVID-19): An in silico approach. Futur J Pharm Sci. 2020; 6: 104.
Sukardiman, Ervina M, Rizki Fadhil Pratama M, Poerwono H, Siswodihardjo S. The coronavirus disease 2019 main protease inhibitor from Androgra phis paniculata (Burm. f) Ness. J Adv Pharm Technol Res. 2020; 11: 15-62.
Swaminathan K, Karunakaran KN, Manoharan PJ, Vidyalakshmi S. SARS-CoV2 multiple target inhibitors from Andrographis Paniculata: An in-silico report. Eur. J. Mol. 2021; 8: 1653-85.
Lim XY, Sue Wen Chan J, Yew Chin Tan T, The PB, Mohd Abd Razak MR, Mohamad S. et al. Andrographis paniculata (Burm. F.) Wall.Ex Nees, Andrographolide, and Andrographolide analogues as SARS-CoV-2 Antivirals? A rapid review. Nat Prod Commun 2021; 16: 1-15.
Wanarat K. Department of Thai traditional and alternative medicine. Andrographis paniculate [online] . 2021 [cited Oct 20, 2021]. Available from: www. dta m.moph.go.th/index.Php/en/thai-massage-research.
Rattanaraksa D, Khempetch R, Poolwiwatchaikool U, Nimitvilai S, Loatrakul O, Srimanee P. The efficacy and safety of Andrographis paniculata extract for treatment of COVID-19 patients with mild symptoms, Nakhonpathom Hospital. Region 4-5 Medical Journal. 2021; 40: 90-102.
Department of Medical Science. Clinical practice guideline for COVID-19 [online]. 2021 [cited Oct 20, 2021]. Available from: covid19.dms.go.th/.
Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39: 175-91.
Cottini M, Lombardi C, Berti A. Obesity is a major risk factor for hospitalization in community-managed COVID-19 pneumonia. Mayo Clin Proc. 2021; 96: 921-31.
Moreno-Noguez M, Rivas-Ruiz R, Roy-García IA, Pacheco-Rosas DO. Moreno-Espinosa S, Flores-Pulido AA. Risk factors associated with SARS-CoV-2 pneumonia in the pediatric population. Bol Med Hosp. Infant Mex. 2021; 78: 251-8. doi: 10.24875/BMHIM.20 000263.
Wang Z, Wang Z. Identification of risk factors for in-hospital death of COVID - 19 pneumonia – lessons from the early outbreak. BMC Infect Dis 2021; 21: 113. doi: 10.1186/s12879-021-05814-4.
Lee HW, Yoon SY, Lee JK, Park TY, Kim DK, Chung, Young E. Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients. Korean J Intern Med. 2021; 36: 1–10.
